Immunotherapy for Ependymoma

"Affirmative, the details published on clinicaltrials.gov indicate that this research project is actively recruiting participants. This study was first advertised on August 1st 2012 and most recently amended on October 23rd 2022; 24 patients need to be recruited from a single location."

"This clinical trial is searching for 24 participants aged between 12 months and 21 years with a diagnosis of ependymoma. In order to be eligible, patients must have received prior standard treatment, including attempted gross total resection followed by fractionated radiation therapy (RT). Additionally, they should not currently suffer from systemic infection or active IV antibiotic therapy; low-dose corticosteroid usage within the past week is also acceptable. Furthermore, their performance status needs to exceed 70 on either Karnofsky or Lansky scales depending on age. Lastly, all candidates need to possess HLA-A2 positive results based on flow cytometry performed at"

"Affirmative. The information published on clinicaltrials.gov suggests that this medical investigation, which was initially announced in August 2012, is presently recruiting participants. A total of 24 people are expected to be recruited from a single site."

"Patients who are younger than 21 years old and have attained at least one year of age can be enrolled in this trial."

"Imiquimod is frequently employed to treat scalp structure, as well as conditions such as condylomata acuminata, facial skin lesions and superficial basal cell carcinoma."

"Presently, there are 21 active studies involving Imiquimod with 5 of the trials at Phase 3. Most of these research sites are located in Houston, Texas but 84 other locations around the world have launched their own clinical investigations using this drug."

"Imiquimod's safety has been established to a limited degree, leading it to receive an assessment score of 1."